Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions

Healthy Volunteer

Interventions

DRUG

ANG-3777 (Therapeutic Dose)

Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted

DRUG

ANG-3777 (Supra-therapeutic Dose)

Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted

DRUG

Placebo

Arms assigned to this intervention will receive normal saline, IV, Fasted

DRUG

Moxifloxacin Hydrochloride

Arms assigned to this intervention will receive 400 mg, Oral, Fasted

Trial Locations (1)

Quotient Sciences, Miami